Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry-Funded CME To Go Way Of Dinosaurs? ACCME Comments Lumber In

Executive Summary

The pharmaceutical industry continues to retrench how it provides continuing medical education in response to public and congressional pressure, but firms are also marshalling for a fight against an outright ban

You may also be interested in...



Social Networking Sites: Small Step For Firms, Giant Leap For Research

As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets

Social Networking Sites: Small Step For Firms, Giant Leap For Research

As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets

CME providers to pay more to be monitored

To finance tighter oversight of continuing medical education programs, the Accreditation Council for Continuing Medical Education is phasing in higher accreditation fees over the next three years. Initial increases will occur in 2009, including a special assessment that could be as high as $7,000, depending on an accredited provider's reported expenses. CME is a major component in the debate about industry influence on physicians' prescribing patterns, prompting Pfizer to curtail its support for CME and ACCME to propose limits on industry funding (1"The Pink Sheet," Sept. 29, 2008, p. 18)

Related Content

UsernamePublicRestriction

Register

PS050146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel